Trial Profile

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 17 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mivocabtagene autoleucel (Primary)
Indications Dermatomyositis; Lupus nephritis; Multiple sclerosis; Myasthenia gravis; Rheumatoid arthritis; Stiff-person syndrome; Systemic scleroderma
Focus Adverse reactions; Pharmacodynamics
Acronyms KYSA-4

Most Recent Events

06 Mar 2026 According to Kyverna Therapeutics media release, data from the trial will be presented at the American Academy of Neurology (AAN) Annual Meeting, taking place from April 18-22, 2026, in Chicago, IL.
16 Feb 2026 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com